Actively Recruiting
Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer
Led by Henan Cancer Hospital · Updated on 2024-05-09
20
Participants Needed
1
Research Sites
113 weeks
Total Duration
On this page
Sponsors
H
Henan Cancer Hospital
Lead Sponsor
K
Kingbio Medical (Beijing) Co., Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to enroll non-small cell lung cancer patients who have undergone at least two rounds of standard treatment for drug resistance/recurrence. Patient-derived Organoid will be established, and drug sensitivity test will be conducted to intervene in the selection of clinical treatment plans. Efficacy evaluation and prognosis analysis will also be conducted. It is hoped that this study will provide a basis for the development of personalized treatment plans.
CONDITIONS
Official Title
Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 75 years at time of informed consent
- Diagnosed with drug-resistant or relapsed non-small cell lung cancer
- Disease progression after at least two systemic treatments
- At least one lesion suitable for tumor biopsy that has not received radiation or other local therapies
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
- Expected survival time greater than 3 months
- Imaging evidence of disease progression after prior treatment before tumor sampling
- Signed informed consent form
- Willing and able to comply with the study plan including visits and tests
You will not qualify if you...
- Extremely weakened overall condition preventing bronchoscopy
- Acute respiratory infections with high fever, asthma attack, or ongoing bleeding from lungs
- History of interstitial lung disease, non-infectious pneumonia, or uncontrolled systemic diseases such as diabetes, hypertension, pulmonary fibrosis, acute lung disease
- Active leptomeningeal disease or brain metastasis
- Other malignancies diagnosed within 5 years except certain skin cancers or carcinoma in situ
- History of immunodeficiency, including positive HIV test
- Untreated active hepatitis B infection
- Serious or uncontrolled systemic diseases
- Pregnant or breastfeeding women
- Any condition deemed unsuitable by the researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Henan Cancer Hospital
Zhengzhou, Henan, China, 450003
Actively Recruiting
Research Team
Q
Qiming Wang, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here